2014.Doxorubicin.HSA
(以“阿霉素（多柔比新）化疗治疗狗的推定性心脏血管肉瘤 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs == 摘要 == <br>”为内容创建页面) |
|||
| 第1行： | 第1行： | ||
| − | + | 阿霉素（多柔比星）化疗治疗狗的推定性心脏血管肉瘤 | |
Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs | Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs | ||
== 摘要 == | == 摘要 == | ||
| + | |||
| + | 64 只狗接受单药多柔比星 （DOX） 治疗推定性心脏血管肉瘤 （cHSA）。客观缓解率（CR + PR）为41%，生物缓解率（CR + PR + SD）或临床获益为68%。接受治疗的狗的中位无进展生存期 （PFS） 为 66 天。该组的中位生存时间 （MST） 为 116 天，与未经治疗的对照犬的 12 天的 MST 相比显着改善 （P = 0.0001）。生物反应与PFS（P < 0.0001）和OS（P < 0.0001）的改善显著相关。单因素分析发现较大的肿瘤大小是与PFS呈负相关的变量。较高的临床获益率和改进的 MST 表明 DOX 在犬 cHSA 中具有活性。 | ||
| + | |||
| + | Sixty-four dogs were treated with single-agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression-free survival (PFS) for treated dogs was 66 days. The median survival time (MST) for this group was 116 days and was significantly improved compared to a MST of 12 days for untreated control dogs (P = 0.0001). Biologic response was significantly associated with improved PFS (P < 0.0001) and OS (P < 0.0001). Univariate analysis identified larger tumour size as a variable negatively associated with PFS. The high rate of clinical benefit and improved MST suggest that DOX has activity in canine cHSA. | ||
<br> | <br> | ||
2024年6月23日 (日) 10:36的版本
阿霉素（多柔比星）化疗治疗狗的推定性心脏血管肉瘤
Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs
摘要
64 只狗接受单药多柔比星 （DOX） 治疗推定性心脏血管肉瘤 （cHSA）。客观缓解率（CR + PR）为41%，生物缓解率（CR + PR + SD）或临床获益为68%。接受治疗的狗的中位无进展生存期 （PFS） 为 66 天。该组的中位生存时间 （MST） 为 116 天，与未经治疗的对照犬的 12 天的 MST 相比显着改善 （P = 0.0001）。生物反应与PFS（P < 0.0001）和OS（P < 0.0001）的改善显著相关。单因素分析发现较大的肿瘤大小是与PFS呈负相关的变量。较高的临床获益率和改进的 MST 表明 DOX 在犬 cHSA 中具有活性。
Sixty-four dogs were treated with single-agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression-free survival (PFS) for treated dogs was 66 days. The median survival time (MST) for this group was 116 days and was significantly improved compared to a MST of 12 days for untreated control dogs (P = 0.0001). Biologic response was significantly associated with improved PFS (P < 0.0001) and OS (P < 0.0001). Univariate analysis identified larger tumour size as a variable negatively associated with PFS. The high rate of clinical benefit and improved MST suggest that DOX has activity in canine cHSA.
